Revenue Performance - Ainos reported nil revenue in Q2 2024, down from $28,555 in Q2 2023, due to the cessation of COVID-19 test kit sales and limited sales of VELDONA Pet[120]. - Revenues for H1 2024 were $20,729, a decrease of $56,990 (73%) compared to $77,719 in H1 2023, primarily due to the cessation of sales of Ainos COVID-19 antigen rapid test kits[131]. Cost of Revenue - The cost of revenue in Q2 2024 was $25,373, a decrease of 55% from $55,817 in Q2 2023, attributed to reduced sales volume[121]. - Cost of revenues in H1 2024 was $52,127, down $104,538 (67%) from $156,665 in H1 2023, attributed to decreased sales volume[132]. Gross Loss - Gross loss from product sales was $25,373 in Q2 2024, slightly improved from a gross loss of $27,262 in Q2 2023[122]. - Gross loss for H1 2024 was $31,398, a reduction of $47,548 (60%) from a gross loss of $78,946 in H1 2023, due to lower sales volume and cost of revenue[133]. Research and Development Expenses - Research and development (R&D) expenses increased by 18% to $1,978,756 in Q2 2024 from $1,671,187 in Q2 2023, driven by co-research and staffing expenditures[123]. - R&D expenses increased by $693,334 (21%) to $4,063,404 in H1 2024 from $3,370,070 in H1 2023, driven by co-research and staffing expenditures[135]. Selling, General and Administrative Expenses - Selling, general and administrative (SG&A) expenses rose by 69% to $1,044,880 in Q2 2024 from $618,149 in Q2 2023, due to increased staffing and professional expenses[125]. - SG&A expenses rose by $693,684 (50%) to $2,074,298 in H1 2024 from $1,380,614 in H1 2023, reflecting increased staffing and professional expenses[137]. Operating Loss - The operating loss increased by 32% to $3,049,009 in Q2 2024 from $2,316,598 in Q2 2023, reflecting ongoing investments in growth strategies[127]. - Operating loss increased by $1,339,470 (28%) to $6,169,100 in H1 2024 compared to $4,829,630 in H1 2023, due to higher operating expenses[139]. Net Loss - Net loss for Q2 2024 was $3,195,022, a 36% increase from $2,349,727 in Q2 2023, primarily due to rising operating expenses[129]. - Net loss for H1 2024 was $6,509,832, an increase of $1,639,630 (34%) from $4,870,202 in H1 2023, primarily due to expanding operating expenses[141]. Financing Activities and Cash Position - Cash provided by financing activities increased significantly to $9,777,500 in H1 2024 from $2,185,974 in H1 2023, reflecting new funding received[145]. - As of June 30, 2024, the company had available cash of $8,014,098, up from $1,885,628 at the end of 2023[142]. Future Plans - Ainos plans to advance its VOC POCT candidate, Ainos Flora, and develop a VOC sensing platform in collaboration with partners[115]. - The company aims to leverage its intellectual property to create multiple revenue streams through commercialization and strategic partnerships[114]. - The company anticipates increased spending on clinical trials and R&D activities to advance its product candidates in the near term[146].

Financial Performance - In Q1 2024, the company reported revenues of $20,729, a decrease of 58% from $49,164 in Q1 2023, primarily due to the cessation of COVID-19 antigen rapid test kit sales[107][108]. - The cost of revenues in Q1 2024 was $26,754, down from $100,848 in Q1 2023, reflecting a decrease in sales volume[109]. - The gross loss for Q1 2024 was $6,025, significantly reduced from a gross loss of $51,684 in Q1 2023, attributed to lower sales volume and reduced cost of revenue[110]. - The company's operating loss increased by 24% to $3,120,091 in Q1 2024 from $2,513,032 in Q1 2023, reflecting ongoing investments in growth strategies[116]. - Net loss for Q1 2024 was $3,314,810, a 32% increase from $2,520,475 in Q1 2023, primarily due to rising operating expenses[119]. Expenses - Research and development (R&D) expenses increased by 23% to $2,084,648 in Q1 2024 from $1,698,883 in Q1 2023, driven by clinical trial fees and staffing expenditures[112]. - Selling, general and administrative (SG&A) expenses rose by 35% to $1,029,418 in Q1 2024 compared to $762,465 in Q1 2023, due to increased share-based compensation and professional expenses[114]. Cash Flow and Investments - As of March 31, 2024, the company had cash and cash equivalents of $1,030,899, down from $1,885,628 at the end of 2023[120]. - Cash used for investing activities increased to $111,280 in Q1 2024 from $72,483 in Q1 2023, primarily due to an increase in refundable deposits and other noncurrent assets[123]. - Cash provided by financing activities decreased to $777,500 in Q1 2024 from $800,000 in Q1 2023, reflecting a decrease of $22,500[124]. Future Plans and Strategies - The company plans to advance its flagship VOC POCT candidate, Ainos Flora, and co-develop a VOC sensing platform with partners, pivoting away from COVID-19 test kits[102]. - The company aims to leverage its intellectual property and develop multiple revenue streams through commercialization of its product portfolio[100]. - The company expects an increase in clinical trial spending to advance VOC POCT and VELDONA drug candidates, along with increased investment in R&D activities[125]. - The company anticipates that cash reserves, business revenues, and potential debt financing will fund operations over the next twelve months, with no assurance of achieving profitability[126]. Accounting and Reporting - Management's financial analysis is based on unaudited condensed financial statements prepared in accordance with U.S. GAAP[127]. - The company evaluates estimates related to inventory valuation, useful lives of property and equipment, and impairment testing of intangible assets on an ongoing basis[128]. - There have been no material changes to critical accounting policies and estimates compared to the previous annual report, except for those discussed in the notes[129]. - The company is classified as a smaller reporting company and is not required to provide additional market risk disclosures[130].

Exhibit 99.1 Ainos Reports First Quarter 2024 Financial Results Strategic focus on VELDONA and AI-powered point-of-care testing continues during 2024 US$9M growth capital secured in May strengthens financial position for executing growth strategy SAN DIEGO, May 13, 2024 /Accesswire/ — Ainos, Inc. (NASDAQ: AIMD, AIMDW) ("Ainos", or the "Company"), a diversified healthcare company focused on the development of novel point-of-care testing ("POCT"), low-dose interferon therapeutics, and synthetic RNA-driven pre ...

Stock Performance - Ainos (NASDAQ:AIMD) stock is experiencing a significant surge with over 7 million shares traded, far exceeding its daily average trading volume of 978,000 shares [1] - The stock has shown volatility throughout the week, with today's movement appearing to be a continuation of earlier rallies [1] - AIMD stock is up 153 4% as of Friday morning but is down 41 7% year-to-date [2] Company Overview - AIMD's prior closing price was $1 12 per share, with a market capitalization of $5 239 million, classifying it as a penny stock [2] - The stock's float is approximately 1 08 million units, making it susceptible to manipulation and potential short squeezes [2] Market Context - The surge in AIMD stock occurs without any clear news or press releases from the company, indicating speculative trading activity [1] - Penny stocks like AIMD are often targeted by retail and day traders, increasing the risk of market manipulation [2]

U.S. Securities and Exchange Commission Washington, D.C. 20549 FORM 10-K ☒ Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Fiscal Year Ended December 31, 2023 Securities registered under Section 12(b) of the Exchange Act. | Title of each class | Trading Symbol(s) | Name of each exchange on which registered | | --- | --- | --- | | | | The Nasdaq Stock Market LLC | | Common Stock | AIMD | (Nasdaq Capital Market) | | | | The Nasdaq Stock Market LLC | | Common Stock ...

Financial Performance - Revenues for 2023 were $122,112, a significant decrease from $3,519,627 in 2022, primarily due to reduced demand for COVID-19 test kits [4]. - Gross profit for 2023 was negative $253,733, compared to a positive gross profit of $1,405,343 in 2022, driven by declines in sales volume and selling price [6]. - Net loss attributable to common stock shareholders was $13,770,549 in 2023, slightly improved from a net loss of $14,006,690 in 2022 [8]. - Total operating expenses decreased to $12,952,663 in 2023 from $15,381,555 in 2022, mainly due to a decline in share-based compensation [7]. - Net loss for 2023 was $13,770,549, slightly improved from a net loss of $14,006,690 in 2022 [24]. - Net loss per common share improved to $(3.36) in 2023 from $(5.14) in 2022 [24]. - Weighted average common shares used in computing net loss per common share increased to 4,098,109 in 2023 from 2,727,458 in 2022 [24]. Research and Development - Research and development (R&D) expenses increased to $7,317,388 in 2023 from $6,845,964 in 2022, while excluding non-cash expenses, R&D expenses decreased to $2,064,658 [13]. - The company initiated the second phase of co-development of an AI Nose-powered VOC sensing platform with NISD and Inabata, aiming for prototype finalization in Q3 2024 [14]. Revenue Diversification - Ainos commenced shipping VELDONA® Pet cytoprotein supplements in Taiwan in Q3 2023, marking a significant step in diversifying revenue streams [2]. - The company signed a Memorandum of Understanding with SIDSCO to explore clinical trials for VELDONA® in the global pet care market [10]. Cash and Assets - Cash and cash equivalents as of December 31, 2023, were $1,885,628, a slight increase from $1,853,362 in 2022 [9]. - Total assets decreased to $31,841,804 as of December 31, 2023, down from $37,109,014 in 2022 [21].

Stock Movement and Trading Activity - Ainos (NASDAQ:AIMD) stock experienced heavy trading with over 7 million shares traded in pre-market, significantly higher than its daily average of 637,000 shares [1] - The stock saw a 57.1% increase as of Monday morning, despite closing Friday down 45.3% year-to-date [2] - On Friday, the stock exhibited unusual trading activity with 4.2 million shares traded, despite a float of only 1.08 million units [2] Company Background and Market Position - Ainos is classified as a penny stock, with a prior closing price of $1.05 per share and a market capitalization of $4.912 million [1] - The company has not released any press statements, SEC filings, or new analyst coverage to explain the recent stock movement [1] Market Context and Investor Considerations - Penny stocks like AIMD are susceptible to manipulation due to their low entry point and market capitalization [2] - The stock's low float and high trading volume suggest potential volatility and speculative trading activity [2]

SAN DIEGO, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Ainos, Inc. (NASDAQ:AIMD, AIMDW))) ("Ainos", or the "Company"), a diversified healthcare company focused on the development of novel point-of-care testing, low-dose interferon therapeutics, and synthetic RNA-driven preventative medicine, today announced that Jack Lu, the Company's Director of Corporate Development, will present live at the Small-Cap Growth Virtual Investor Conference, hosted by VirtualInvestorConferences.com, on February 7, 2024. DATE: February 7 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q _____________________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ Commission File No. 0-20791 _____________________________________________ AINOS, IN ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from____to____ Commission File No. 0-20791 AINOS, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organ ...